Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

IF 8.4 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2026-03-17 DOI:10.1038/s41523-026-00925-0

Alan Su, Erin C Hong, Nicole Moxon, Staci L Mellinger, Tracy Kelly, Alison K Conlin, Zheng Zhu Topp, Philippa Newell, Nicole Fredrich, Kristen P Massimino, Yaping Wu, Maritza Martel, William L Redmond, Shaghayegh Aliabadi-Wahle, Zhaoyu Sun, James Imatani, Sasha E Stanton, Douglas A Hanes, Michael Simanonok, Wesley Rosales, Tyler J Nielsen, David B Page

引用次数: 0

Abstract

We previously showed the feasibility and immunologic effects of multivalent peri-lymphatic cytokine injection (IRX-2) in early-stage breast cancer. We now report outcomes of a pilot evaluation of IRX-2 + pembrolizumab induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC). Single-cycle induction was associated with radiographic tumor regression, tumor necrosis, immune infiltration, and high pathologic complete response rate following platinum-sparing chemo-immunotherapy. Further investigation of peri-lymphatic cytokines in TNBC is warranted.

查看原文本刊更多论文

淋巴细胞因子（IRX-2）在三阴性乳腺癌新辅助化疗免疫治疗前的免疫诱导作用。

我们之前已经证明了多价淋巴周围细胞因子注射（IRX-2）治疗早期乳腺癌的可行性和免疫效果。我们现在报告了在三阴性乳腺癌（TNBC）新辅助化疗免疫治疗前IRX-2 +派姆单抗诱导的试点评估结果。单周期诱导与放射学上的肿瘤消退、肿瘤坏死、免疫浸润和保铂化疗免疫治疗后的高病理完全缓解率相关。进一步研究淋巴周围细胞因子在TNBC中的作用是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.